Ad hoc announcement pursuant to Art. 53 LRComparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth ...

Novo Nordisk NVO is scheduled to report its third-quarter 2025 results before the opening bell on Nov. 5, 2025. The Zacks ...

A global analysis of 125 turmeric supplements across five major markets revealed widespread inconsistencies in labeling, ...

A malaria test commonly used across Asia and South America “is not fit for purpose”, researchers have claimed.

Q3 2025 Earnings Call November 3, 2025 4:30 PM ESTCompany ParticipantsRobert DeVitaDavid Hung - Founder, President, CEO ...

Findings further demonstrate the effectiveness of Roche's approved medicines in advancing treatment standards for people with blood disorders Data from innovative pipeline signals progress ...

The chronic progressive multiple sclerosis market size is anticipated to grow during the forecast period (2025–2034).

Prior authorizations (PAs) continue to be one of the biggest hurdles to timely patient care. A recent survey found that 93% of physicians say that the PA process can delay treatment and three-quarters ...

First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session ...

A spokesperson told the Telegraph that while the line on the rapid test is sometimes faint, the product label ... data is awaited.” Dr Stephen Woolley, a senior lecturer in medical parasitology and ...

Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte’s MPN, GVHD and hematology ...